EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
14.75
+1.27 (9.42%)
At close: Aug 14, 2026, 4:00 PM EDT
15.10
+0.35 (2.37%)
After-hours: Aug 14, 2026, 7:59 PM EDT
EyePoint Revenue
EyePoint had revenue of $507.00K in the quarter ending June 30, 2026, a decrease of -90.49%. This brings the company's revenue in the last twelve months to $2.79M, down -94.63% year-over-year. In the year 2025, EyePoint had annual revenue of $31.37M, down -27.50%.
Revenue (ttm)
$2.79M
Revenue Growth
-94.63%
P/S Ratio
456.11
Revenue / Employee
$13,028
Employees
214
Market Cap
1.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.37M | -11.90M | -27.50% |
| Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
| Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
| Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
| Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
| Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
| Dec 31, 2019 | 20.37M | 15.79M | 345.53% |
| Dec 31, 2018 | 4.57M | 1.61M | 54.37% |
| Jun 30, 2018 | 2.96M | -4.58M | -60.72% |
| Jun 30, 2017 | 7.54M | 5.92M | 365.37% |
| Jun 30, 2016 | 1.62M | -24.95M | -93.90% |
| Jun 30, 2015 | 26.57M | 23.09M | 664.90% |
| Jun 30, 2014 | 3.47M | 1.33M | 62.06% |
| Jun 30, 2013 | 2.14M | -1.38M | -39.22% |
| Jun 30, 2012 | 3.53M | -1.44M | -28.98% |
| Jun 30, 2011 | 4.97M | -18.09M | -78.46% |
| Jun 30, 2010 | 23.05M | 10.89M | 89.55% |
| Jun 30, 2009 | 12.16M | 8.69M | 249.88% |
| Jun 30, 2008 | 3.48M | 1.69M | 94.73% |
| Jun 30, 2007 | 1.79M | 749.00K | 72.30% |
| Jun 30, 2006 | 1.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 397.50M |
| MannKind | 393.63M |
| Apnimed | 120.15M |
| Immatics | 43.00M |
| Omeros | 38.42M |
| Inhibrx Biosciences | 1.30M |
EYPT News
- 1 day ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - EyePoint price target raised to $55 from $47 at Cantor Fitzgerald - TheFly
- 10 days ago - EyePoint price target lowered to $27 from $30 at H.C. Wainwright - TheFly
- 11 days ago - EyePoint reports Q2 EPS ($1.09), consensus (96c) - TheFly
- 11 days ago - EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 11 days ago - EyePoint Earnings release: Q2 2026 - Filings
- 11 days ago - EyePoint Quarterly report: Q2 2026 - Filings
- 11 days ago - Citi opens ‘upside 90-day catalyst watch’ on EyePoint into data - TheFly